RxDoctor Payments Data

Hazel Wiley, DO

Neurology · Lauderdale Lakes, FLNPI 1821208794

Payments from drug & device makers

$20,484in general payments, 2019–2025

Across 837 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$2K
  • UCB, Inc.$2K
  • AbbVie$2K
  • Biogen$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • plus $12K from 52 others

What the payments were for

  • Speaking & faculty fees$1291%
  • Food & beverage$20,12498%
  • Education$2311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.61$1,893
UCB, Inc.65$1,853
AbbVie(2 entities)89$1,664
Biogen54$1,175
Biohaven Pharmaceuticals, Inc.28$1,104
Lilly USA, LLC43$1,073
Eisai Inc.36$1,066
Teva Pharmaceuticals USA, Inc.56$981
Otsuka America Pharmaceutical, Inc.24$826
Amneal Pharmaceuticals LLC36$797
MDD US Operations, LLC27$706
Sanofi18$558
SK Life Science, Inc.20$479
Argenx US, Inc.16$456
Neurelis, Inc.14$443
Lundbeck LLC20$439
Upsher-smith Laboratories LLC35$403
Johnson & Johnson9$356
Pfizer17$304
Amgen14$304
Tanabe Pharma America, Inc.12$298
Sunovion Pharmaceuticals Inc.14$273
E.r. Squibb & Sons, L.L.C.3$272
Biohaven Pharmaceutical Holding Company Ltd.19$214
AstraZeneca(2 entities)5$212
Novartis10$204
Medtronic1$199
Sumitomo Pharma America, Inc.9$185
ANI Pharmaceuticals, Inc.12$184
C2n Diagnostics, LLC6$181
Neurocrine Biosciences, Inc.4$156
Supernus Pharmaceuticals, Inc.11$151
Mallinckrodt Hospital Products Inc.4$140
TG Therapeutics, Inc.3$92
Aucta Pharmaceuticals, Inc.4$88
Axsome Therapeutics, Inc.4$88
Merz Pharmaceuticals, LLC3$70
Bristol Myers Squibb4$66
Vanda Pharmaceuticals Inc.3$57
Acadia Pharmaceuticals Inc2$47
Impel Pharmaceuticals Inc.3$46
Bausch & Lomb, A Division Of Bausch Health US, LLC2$44
Jazz Pharmaceuticals Inc.1$38
Abbott2$37
Penumbra, Inc.1$25
Aprecia Pharmaceuticals, LLC1$24
Shire North American Group Inc1$24
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$23
Insightec,inc1$21
Scilex Pharmaceuticals Inc.1$21
Promius Pharma LLC1$19
Vertical Pharmaceuticals, LLC1$19
Assertio Therapeutics, Inc.1$16
Livanova USA, Inc.1$16
Avion Pharmaceuticals1$16
Boston Scientific1$15
Currax Pharmaceuticals LLC1$14
Arbor Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,484 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$67,793
Medicare patients
243
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole41$79,411
AptiomEslicarbazepine Acetate32$40,268
Nurtec OdtRimegepant Sulfate18$40,031
RytaryCarbidopa/Levodopa23$30,441
BriviactBrivaracetam18$26,253
FycompaPerampanel26$24,810
UbrelvyUbrogepant16$22,520
Lacosamide90$21,254
VimpatLacosamide15$17,277
Emgality PenGalcanezumab-Gnlm19$14,133
Memantine Hcl322$7,669
Memantine Hcl ErMemantine Hcl51$7,376
Entacapone33$4,179
Donepezil Hcl456$3,619
Carbamazepine ErCarbamazepine15$2,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$826$79,41141 claims
UCB, Inc.Briviact, Vimpat$1,853$43,52933 claims
Sunovion Pharmaceuticals Inc.Aptiom$273$40,26832 claims
PfizerNurtec Odt$304$40,03118 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$797$31,15842 claims
Eisai Inc.Fycompa$1,066$24,81026 claims
AbbVieUbrelvy$1,664$22,52016 claims
Upsher-smith Laboratories LLCTopiramate$403$1,112158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Lauderdale Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →